PathMaker Biosystems

PathMaker Biosystems is a clinical-stage bioelectronic medicine company developing non-invasive systems for the treatment of serious neurological disorders. The company's proprietary technology platform, Signal-Specific Neuromodulation (SSN), enables the delivery of multi-site stimulation to treat conditions characterized by neural hyperexcitability or impaired motor function. Their lead product, MyoRegulator, is a first-in-class non-invasive device designed to treat muscle spasticity, while their second candidate, MyoControl, targets Amyotrophic Lateral Sclerosis (ALS). By replacing or supplementing pharmacological interventions with targeted electronic signals, PathMaker aims to provide safer and more effective therapeutic options for patients with chronic neurological conditions.